The global newborn screening market size is calculated at USD 909.18 million in 2024, grew to USD 977.83 million in 2025 and is predicted to surpass around USD 1,882.59 million by 2034, expanding at a solid CAGR of 7.55% between 2024 and 2034. The Asia Pacific newborn screening market size is valued at USD 300.94 million in 2024 and is representing a solid CAGR of 7.56% during the forecast period.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Newborn Screening Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Newborn Screening Market, by Product, 2024-2034
8.1.1 Instruments
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Reagents
8.1.2.1. Market Revenue and Forecast (2021-2034)
9.1. Newborn Screening Market, by Technology, 2024-2034
9.1.1. Tandem Mass Spectrometry
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Pulse Oximetry
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Enzyme Based Assay
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. DNA Assay
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Electrophoresis
9.1.5.1. Market Revenue and Forecast (2021-2034)
9.1.6. Others
9.1.6.1. Market Revenue and Forecast (2021-2034)
10.1. Newborn Screening Market, by Test Type, 2024-2034
10.1.1. Dry Blood Spot Test
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. CCHD
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Hearing Screen
10.1.3.1. Market Revenue and Forecast (2021-2034)
11.1. North America
11.1.1. Market Revenue and Forecast, by Product (2021-2034)
11.1.2. Market Revenue and Forecast, by Technology (2021-2034)
11.1.3. Market Revenue and Forecast, by Test Type (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Product (2021-2034)
11.1.4.2. Market Revenue and Forecast, by Technology (2021-2034)
11.1.4.3. Market Revenue and Forecast, by Test Type (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Product (2021-2034)
11.1.5.2. Market Revenue and Forecast, by Technology (2021-2034)
11.1.5.3. Market Revenue and Forecast, by Test Type (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product (2021-2034)
11.2.2. Market Revenue and Forecast, by Technology (2021-2034)
11.2.3. Market Revenue and Forecast, by Test Type (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Product (2021-2034)
11.2.4.2. Market Revenue and Forecast, by Technology (2021-2034)
11.2.4.3. Market Revenue and Forecast, by Test Type (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Product (2021-2034)
11.2.5.2. Market Revenue and Forecast, by Technology (2021-2034)
11.2.5.3. Market Revenue and Forecast, by Test Type (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Product (2021-2034)
11.2.6.2. Market Revenue and Forecast, by Technology (2021-2034)
11.2.6.3. Market Revenue and Forecast, by Test Type (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Product (2021-2034)
11.2.7.2. Market Revenue and Forecast, by Technology (2021-2034)
11.2.7.3. Market Revenue and Forecast, by Test Type (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product (2021-2034)
11.3.2. Market Revenue and Forecast, by Technology (2021-2034)
11.3.3. Market Revenue and Forecast, by Test Type (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Product (2021-2034)
11.3.4.2. Market Revenue and Forecast, by Technology (2021-2034)
11.3.4.3. Market Revenue and Forecast, by Test Type (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Product (2021-2034)
11.3.5.2. Market Revenue and Forecast, by Technology (2021-2034)
11.3.5.3. Market Revenue and Forecast, by Test Type (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Product (2021-2034)
11.3.6.2. Market Revenue and Forecast, by Technology (2021-2034)
11.3.6.3. Market Revenue and Forecast, by Test Type (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Product (2021-2034)
11.3.7.2. Market Revenue and Forecast, by Technology (2021-2034)
11.3.7.3. Market Revenue and Forecast, by Test Type (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product (2021-2034)
11.4.2. Market Revenue and Forecast, by Technology (2021-2034)
11.4.3. Market Revenue and Forecast, by Test Type (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Product (2021-2034)
11.4.4.2. Market Revenue and Forecast, by Technology (2021-2034)
11.4.4.3. Market Revenue and Forecast, by Test Type (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Product (2021-2034)
11.4.5.2. Market Revenue and Forecast, by Technology (2021-2034)
11.4.5.3. Market Revenue and Forecast, by Test Type (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Product (2021-2034)
11.4.6.2. Market Revenue and Forecast, by Technology (2021-2034)
11.4.6.3. Market Revenue and Forecast, by Test Type (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Product (2021-2034)
11.4.7.2. Market Revenue and Forecast, by Technology (2021-2034)
11.4.7.3. Market Revenue and Forecast, by Test Type (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product (2021-2034)
11.5.2. Market Revenue and Forecast, by Technology (2021-2034)
11.5.3. Market Revenue and Forecast, by Test Type (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Product (2021-2034)
11.5.4.2. Market Revenue and Forecast, by Technology (2021-2034)
11.5.4.3. Market Revenue and Forecast, by Test Type (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Product (2021-2034)
11.5.5.2. Market Revenue and Forecast, by Technology (2021-2034)
11.5.5.3. Market Revenue and Forecast, by Test Type (2021-2034)
12.1. Bio-Rad Laboratories
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Agilent Technologies
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Waters Corporation
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Natus Medical
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Trivitron Healthcare
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. GE Lifesciences
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. PerkinElmer Inc
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. AB SCIEX
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Covidien plc
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Masimo
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample